

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q86049

Nicoletta BIANCHI, et al.

Application No.: 10/522,737

Group Art Unit: 1614

Confirmation No.: 8521

Examiner: Brian Yong S KWON

Filed: October 12, 2005

For: USE OF ANGELICIN AND ITS STRUCTURAL ANALOGUES FOR THE
TREATMENT OF THALASSEMIA

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825**

MAIL STOP SEQUENCE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In connection with the Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the contents of the 1-page Sequence Listing being filed with the present application, and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same; and
2. all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that

Statement to Support Submission of Sequence Listing
Application No.: 10/522,737

Attorney Docket No.: Q86049

such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,



H. Janice Lee, Ph.D.

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: February 25, 2009